A Human Clinical Trial to Evaluate S-2P-NE-01, a Nasal Vaccine for SARS-CoV-2
Latest Information Update: 24 Nov 2020
At a glance
- Drugs Intranasal COVID 19 vaccine-BlueWillow Biologics (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions
- 24 Nov 2020 New trial record
- 10 Nov 2020 According to a Medigen Vaccine Biologics media release, BlueWillow Biologics plans to rapidly advance S-2P-NE-01 into human clinical trials.